Effects of pH, electric current, and enzyme inhibitors on iontophoresis of delta sleep-inducing peptide

Drug Development and Industrial Pharmacy

Volumn 24, Issue 5, 1998, Pages 431-438

  Chiang, Chiao Hsi ^a,b   Shao, Chun Hui ^a   Chen, Jiin Long ^a  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b Grad Inst of Pharmacognosy Science   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

1,10 PHENANTHROLINE; DELTA SLEEP INDUCING PEPTIDE; DEOXYCHOLATE SODIUM; EDETIC ACID; ENZYME INHIBITOR; METALLOPROTEINASE;

ANIMAL TISSUE; ARTICLE; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG POTENTIATION; DRUG STABILITY; ELECTRIC CURRENT; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IONTOPHORESIS; ISOELECTRIC POINT; NONHUMAN; PH; RABBIT; SKIN; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0031746126     PISSN: 03639045     EISSN: None     Source Type: Journal    
DOI: 10.3109/03639049809085640     Document Type: Article

References (22)

1. A. K. Banga, Y. W. Chien, Int. J. Pharm., 48, 15 (1988).
2. R. R. Borchardt, N. A. Mazer, J. H. Rytting, E. Shek, E. Ziv, E. Ouitou, and W. I. Higuchi, J. Pharm. Sci., 78, 883 (1989).
3. A. T. P. Skrabanja, A. L. J. De Meere, R. A. De Ruiter, and P. J. M. Van Den Oetelaar, J. Pharm. Sci. Technol., 48, 311 (1994).
4. P. Langguth, H. P. Merkle, and G. L. Amidon, Pharm. Res., 11, 528 (1994).
5. J. P. F. Bai and L. L. Chang, Pharm. Res., 12, 164 (1995).
6. H. Sasaki, C. Tei, K. Yamamura, K. Nishida, and J. E. Nakamura, Pharm. Pharmacol., 46, 871 (1994).
7. H. Critchley, S. S. Davis, N. F. Farraj, and L. Illum, J. Pharm. Pharmacol., 46, 651 (1994).
8. T. Morita, A. Yamamoto, Y. Takakura, M. Hashida, and H. Sezaki, Pharm. Res., 11, 909 (1994).
9. B. Kari, Diabetes, 35, 217 (1986).
10. B. R. Meyer, H. L. Katzeff, J. C. Eschbach, J. Trimmer, S. B. Zacharias, S. Rosen, and D. Sibalis, Am. J. Med. Sci., 297, 321 (1989).
11. B. R. Meyer, W. Kreis, J. Eschbach, V. O'Mara, S. Rosen, and D. Sibalis, Clin. Pharmacol. Ther. 44, 607 (1988).
12. C. R. Behl, S. Kumar, A. W. Malick, S. D. Del Terzo, W. I. Higuchi, and R. A. Nash, J. Pharm. Sci., 78, 355 (1989).
13. M. Monnier, L. Dudler, R. Gachter, P. F. Maier, H. J. Tobler, and G. A. Schoenenberger, Experientia, 33, 548 (1977).
14. R. M. Salieva, K. Yanovskii, R. Ratsak, Ya. I. Trofimova, P. Oeme, K. V. Sudakov, and E. A. Yumatov, Zh. Vyssh. Nervn. Deyat., 41, 558 (1991).
15. F. Bes, W. Hofman, J. Schuur, and C. V. Boxtel, Neuropsychobiology, 26, 193 (1992).
16. F. Nyberg, M. Thornwall, and J. Hetta, Biochem. Biophys. Res. Commun. 167, 1256 (1990).
17. V. H. L. Lee, R. D. Traver, and M. E. Taub, Enzymatic barriers to peptide and protein drug delivery, in Peptide and Protein Drug Delivery, (V. H. L. Lee, ed.), Marcel Dekker, New York, 1991, pp. 303-358.
18. M. Deschodt-Lanckman and A. D. Strosberg, FEBS Lett., 152, 109 (1983).
19. J. Singh, and M. S. J. Roberts, Drug Design Deliv., 4, 1 (1984).
20. R. E. Dickerson and I. Geis, The Structure and Action of Proteins, Harper & Row, New York, 1969, pp. 24-43.
21. M. I. Pikal and S. Shah, Pharm. Res., 7, 213 (1990).
22. R. R. Burnette and B. Ongpipattanakul, J. Pharm. Sci., 76, 765 (1987).